Get started
I-SENS, INC.II

I-SENS, INC.

16,010KRWD
+10+0.06%
At close at Mar 21, 07:45 GMT
KRW
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

099190 fundamentals

Key facts

Market capitalization‪440.26 B‬KRW
Dividend yield (indicated)0.62%
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−56.04KRW
Founded2000
Employees (FY)—
CEO—
Websitei-sens.co.kr
About

i-SENS, Inc. engages in the development, manufacture and sales of medical sensors and measuring instruments based on electrochemical and biosensor technologies. It operates through the Blood Glucose Meter and Point-of-Care business divisions. The Blood Glucose Meter business division is composed of a diagnostic device that allows to measure the amount of glucose in the blood and consists of a blood glucose meter, blood glucose strip, and lancet. The Point-of-Care business division consists of diagnostic testing conducted at the patient’s site, rather than in a central laboratory. The company was founded by Geun-Sig Cha and Hak-Hyun Nam on May 4, 2000 and is headquartered in Seoul, South Korea.

Ownership
‪‪27.64 M‬‬
Free Float shares
‪‪17.71 M‬‬ (64.08%)
Closely held shares
‪‪9.93 M‬‬ (35.92%)
Free Float shares
‪‪17.71 M‬‬ (64.08%)
Closely held shares
‪‪9.93 M‬‬ (35.92%)
Capital structure
Market cap
‪‪440.26 B‬‬
Enterprise value
‪‪440.26 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪440.26 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
—
Valuation ratios
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪25.00‬
‪50.00‬
‪75.00‬
‪100.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−3.6%‬
‪−2.4%‬
‪−1.2%‬
‪0.0%‬
‪1.2%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−30.00 B‬‬
‪0.00‬
‪‪30.00 B‬‬
‪‪60.00 B‬‬
‪‪90.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−90.00 B‬‬
‪‪−45.00 B‬‬
‪0.00‬
‪‪45.00 B‬‬
‪‪90.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−90.00 B‬‬
‪‪−45.00 B‬‬
‪0.00‬
‪‪45.00 B‬‬
‪‪90.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Medical Chemicals and Biosensors
Other
By country
Period: 2024
United States
South Korea
Asia
Other
Europe

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪21.00 B‬‬
‪‪42.00 B‬‬
‪‪63.00 B‬‬
‪‪84.00 B‬‬
Actual
Estimate
Earnings
Next:Jan 29, 2026
2021
2022
2023
2024
2025
‪−400.00‬
‪0.00‬
‪400.00‬
‪800.00‬
‪‪1.20 K‬‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
−178.44%
Payout ratio (TTM)
Dividend yield TTM
0.62%
Last payment
100.00
Last ex-date
Dec 27, 2024
Dividend history
‪0.3%‬
‪0.5%‬
‪0.7%‬
‪0.9%‬
‪1.1%‬
2020
2021
2022
2023
2024
‪0.00‬
‪50.00‬
‪100.00‬
‪150.00‬
‪200.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−60.00 B‬‬
‪0.00‬
‪‪60.00 B‬‬
‪‪120.00 B‬‬
‪‪180.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
No data available
There's currently no assets and liabilities data to show.